(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA, in a rare move, cuts space station mission short after an astronaut's medical issue - 2The Force of Systems administration: Individual Examples of overcoming adversity
- 3Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel
- 4The Manual for Decent European Urban communities in 2024
- 5Are protests pushing Iran's Islamic regime toward a tipping point?
- 2024's Savvy Home Gadgets for an Associated Way of life
- 'Everyone in this prison has had family killed or shot'
- British-Egyptian dissident apologises for tweets as Tories push for UK deportation
- Explosions heard across Tehran after IDF announces wave of strikes on regime terror targets
- How to watch NASA's Artemis 2 astronauts launch to the moon on April 1
- Israel's fractured opposition hands Netanyahu a full term
- Cheetos and Doritos to launch new versions without artificial dyes
- Death toll from floods in Afghanistan rises to 61
- Warming winters lead to more nitrate pollution in the drinking water near farms
